Fusion Pharmaceuticals

23 articles with Fusion Pharmaceuticals

• Fusion Pharmaceuticals Initiates Multi-Dose Portion of Phase 1 Trial of FPI-1434 in Patients with Advanced Solid Tumors

  12/10/2020

  Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the first patient has been dosed in the multi-dose portion of the Phase 1 study evaluating [225Ac]-FPI-1434 (FPI-1434) in patients with advanced solid tumors.

• Fusion Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference

  11/12/2020

   Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will participate in a "fireside chat" presentation at the Jefferies Virtual London Healthcare Conference on Thursda

• Fusion Pharmaceuticals Announces Third Quarter 2020 Financial Results and Business Update

  11/10/2020

  - Multi-dosing portion of Fusion's Phase 1 study of FPI-1434 on track to be initiated in Q4 2020 - Company executes collaboration agreement with AstraZeneca to grow pipeline of next-generation radiopharmaceuticals

• Fusion Pharmaceuticals Appoints Barbara Duncan as Chairperson of the Board of Directors

  11/2/2020

  Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the appointment of Barbara Duncan,

• Fusion Pharmaceuticals Announces Collaboration with AstraZeneca to Develop and Commercialize Next-Generation Radiopharmaceuticals and Combination Therapies

  11/2/2020

  Collaboration Combines Fusion's Targeted Alpha Therapies (TATs) Platform with AstraZeneca's Antibody and Oncology Portfolio to Create Novel Cancer Therapies

• Fusion Pharmaceuticals Appoints Maria Stahl as Chief Legal Officer

  9/29/2020

   Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the appointment of Maria Stahl as chief legal officer.

• Fusion Pharmaceuticals to Present at the Morgan Stanley Virtual 18th Annual Global Healthcare Conference

  9/10/2020

  Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will participate in a "fireside chat" presentation at the Morgan Stanley Virtual 18th Annual Global Healthcare Conference on Thursday, September 17, 2020 at 11:00am EDT

• Fusion Pharmaceuticals Announces Second Quarter 2020 Financial Results and Business Update

  8/11/2020

  Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced financial results for the second quarter ended Ju

• Fusion Pharmaceuticals to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

  8/5/2020

  Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that Chief Executive Officer John Valliant , Ph.D., will present a company overview at the 2020 Wedbush PacGrow Healthcare Virtual Conference

• Fusion Pharmaceuticals Announces Pricing of Initial Public Offering - June 26, 2020

  6/26/2020

  Fusion Pharmaceuticals Inc., a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, announced the pricing of its initial public offering of 12,500,000 common shares at a public offering price of $17.00 per share.

• Fusion Pharmaceuticals Appoints James J. O’Leary, M.D. as Chief Medical Officer

  3/23/2020

  Fusion Pharmaceuticals Inc., a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines to treat a broad range of cancers, today announced the appointment of James J. O’Leary, M.D., as chief medical officer (CMO).

• Fusion Pharmaceuticals Announces Appointment of Steven Gannon to Board of Directors

  3/4/2020

  Fusion Pharmaceuticals Inc., a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines to treat a broad range of cancers, today announced the appointment of Steven Gannon to its Board of Directors.

• Fusion Pharmaceuticals Announces Appointment of Pablo J. Cagnoni, M.D., to Board of Directors

  2/6/2020

  Feb. 6, 2020 13:30 UTC Fusion Pharmaceuticals Announces Appointment of Pablo J. Cagnoni, M.D., to Board of Directors BOSTON & HAMILTON, Ontario--( BUSINESS WIRE )-- Fusion Pharmaceuticals Inc. , a clinical-stage precision oncology company developing targeted alpha therapeutics, today announced the appointment of Pablo J. Cagnoni, M.D., to the board of directors. Dr. Cagnoni's appointment as an independent director adds an oncology drug development leader

• Fusion Pharmaceuticals To Present at The 38th Annual J.P. Morgan Healthcare Conference

  1/10/2020

  The presentation will take place on Thursday, January 16, 2020 at 11:00am PST.

• Fusion Pharmaceuticals Announces Poster Presentation at ASCO 2019

  5/16/2019

  Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, announced that it will present a poster at the 2019 American Society of Clinical Oncology meeting, which is being held from May 31 to June 4, 2019, at the McCormick Place Convention Center in Chicago, Illinois.

• Fusion Pharmaceuticals Raises $105 Million in Oversubscribed Series B Financing

  4/2/2019

  Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, today announced the completion of a $105 million Series B financing led by Varian and new investor OrbiMed.

• 

  BioSpace Movers and Shakers: March 8

  3/8/2019

  Perhaps the biggest mover and shaker announcement this week was the unexpected resignation of Scott Gottlieb, commissioner of the U.S. Food and Drug Administration. Gottlieb will leave his post later this month to spend more time with his family.

• Fusion Pharmaceuticals Announces Appointment of John J. Crowley as Chief Financial Officer

  3/4/2019

  Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, announced the appointment of John J. Crowley as Chief Financial Officer.

• Fusion Pharma Announces First Patient Dosing in a Phase 1 Clinical Trial of [225Ac]-FPI-1434 Injection in Patients with Advanced Solid Tumors

  2/19/2019

  Fusion Pharmaceuticals, a biopharmaceutical company focused on radiotherapeutics, announced that the first patient was dosed in a Phase 1, first-in-human clinical trial of lead product candidate [225Ac]-FPI-1434 in patients with advanced solid tumors.

• Fusion Pharma Announces Formation of Advisory Board

  7/16/2018

  Inaugural Advisory Board Includes Internationally Renowned Experts In Oncology and Radiation Therapy.